

Date and Time: 11th January 2013 10:00-16:00

Minutes: Confirmed

Multiple Sclerosis GDG Meeting 4

Place: NCGC Boardroom, 180 Great Portland Street, London, W1W 5QZ

Present: GDG

1. Paul Cooper (Chair)	PC
2. Jeremy Chataway	JC
3. Peter Brex	PB
4. Wendy Hendrie	WH
5. Susan Hourihan	SH
6. Pamela Bostock	PAB
7. Noreen Barker	NB
8. Richard Warner	RW
9. Aleks de Gromoboy	ADG
10. Ann Hodgson	AH
11. Emma Rowe	ER
12. David Kernick	DK

NCGC Technical team

13. Norma O'Flynn	NOF
14. Sharon Swain	SS
15. Mark Perry	MP
16. Lola Adedokun	LA
17. Amy Kelsey	AK
18. Lina Gulhane – presents for note 6	LG
19. Krishna Chinthapalli	KC

NICE

20. Clifford Middleton	CM
------------------------	----

Notes

Notes

1. The Chair welcomed the group to the Multiple Sclerosis Guideline Development Group (GDG) meeting 4. There were no apologies. The Chair then briefed the group on the meetings objectives.
2. The Chair asked the GDG to declare any personal specific, personal non-specific, non-personal specific or non-personal non-specific interests

PB declared the following personal pecuniary interest: he attended an Advisory Board for Biogen Idec for which he received an honorarium in December 2012.. He also declared the following non-personal pecuniary interest: he chaired and spoke at a meeting about long-term effects of disease modifying therapies in MS organised by his department and sponsored by Bayer. He did not accept an honorarium for his involvement in this meeting. He also declared the following personal non-pecuniary interest: he lectured at an MS trust Study day in MS and pregnancy in November 2012.

All other GDG members had no change in their previous declarations.

3. The Chair introduced Mark Perry, NCGC Research Fellow, who gave a presentation on the clinical evidence of rehabilitation provided in different settings for adults with MS. The GDG then discussed the evidence presented and agreed that further research is needed in this area. The Chair thanked MP for his presentation.
4. The Chair then led discussion on the review of the key diagnostic criteria from GDG 3. The GDG discussed and updated the draft recommendations.
5. The Chair then introduced MP, who led discussion on the review of the information and support recommendations from GDG 3. The GDG discussed and updated the recommendations.
6. The Chair then introduced Sharon Swain, NCGC Senior Research Fellow, and MP who led discussion with the GDG on the research protocols for 5 clinical questions. The following research protocols were discussed by the group:
 - For adults with MS, what is the clinical evidence and cost effectiveness of the pharmacological treatment of oscillopsia?
 - For adults with MS what is the clinical evidence and cost effectiveness of pharmacological treatment of spasticity?
 - Does the use of structured assessment(s) compared with non-structured assessment(s) improve patient and carer outcomes for people with MS for the following disabilities and functional problems? What is the optimal timing of a structured assessment? What should be the frequency of a structured assessment?
 - For adults with MS, what is the clinical evidence and cost effectiveness of the following: omega-3 fatty acids; omega-6 fatty acids and acupuncture?
 - For adults with MS, what is the clinical and cost effectiveness of pharmacological management of emotionalism with antidepressants?

7. The GDG discussed advance notice of GDG dates. AK will send out the remainder of the

Notes

2013 GDG dates as soon as possible. The Chair closed the meeting and thanked everyone for attending.

Date, time and venue of the next meeting

8. Wednesday 20th February 2013, 10:00-16:00, Linacre Room, Royal College of Physicians, 11 St Andrews Place, London NW1 4LE.